Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ ...

Removing the fallopian tubes during routine gynecological surgery reduced the risk of serous ovarian cancer by nearly 80%.

Removing fallopian tubes, a procedure known as opportunistic salpingectomy, may help prevent the development of ovarian cancer, according to a consensus statement from the Ovarian Cancer Research ...

Performing an opportunistic salpingectomy (removal of fallopian tubes) reduces the risk of serous ovarian cancer by up to 78% ...

The Ovarian Cancer Research Alliance is recommending an aggressive ovarian cancer prevention strategy: Remove a patient’s fallopian tubes if that person is undergoing pelvic surgery, The Washington ...

Please provide your email address to receive an email when new articles are posted on . Implementing fallopian tube recanalization — an interventional radiology ...

To prevent more cases of ovarian cancer, a major research and advocacy group is suggesting an aggressive prevention strategy: remove a woman's fallopian tubes if she is undergoing pelvic surgery for ...

Add Yahoo as a preferred source to see more of our stories on Google. Because 70% of ovarian cancer begins in the fallopian tubes, the Ovarian Cancer Research Alliance is “encouraging people who are ...

The fallopian tube is the site of fertilization, where once a month for the duration of a female's post-pubescent, pre-menopausal life, an egg is moved from the ovary, ready for fertilization by a ...